Serum Caffeine and Metabolites Are Reliable Biomarkers of Early Parkinson Disease

Overview

Journal Neurology

Specialty Neurology

Date 2018 Jan 5

PMID 29298852

Citations 42

Authors

Motoki Fujimaki

Shinji Saiki

Yuanzhe Li

Naoko Kaga

Hikari Taka

Taku Hatano

Kei-Ichi Ishikawa

Yutaka Oji

Akio Mori

Ayami Okuzumi

Takahiro Koinuma

Shin-Ichi Ueno

Yoko Imamichi

Takashi Ueno

Yoshiki Miura

Manabu Funayama

Nobutaka Hattori

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the kinetics and metabolism of caffeine in serum from patients with Parkinson disease (PD) and controls using liquid chromatography-mass spectrometry.

Methods: Levels of caffeine and its 11 metabolites in serum from 108 patients with PD and 31 age-matched healthy controls were examined by liquid chromatography-mass spectrometry. Mutations in caffeine-associated genes were screened by direct sequencing.

Results: Serum levels of caffeine and 9 of its downstream metabolites were significantly decreased even in patients with early PD, unrelated to total caffeine intake or disease severity. No significant genetic variations in or , encoding cytochrome P450 enzymes primarily involved in metabolizing caffeine in humans, were detected compared with controls. Likewise, caffeine concentrations in patients with PD with motor complications were significantly decreased compared with those without motor complications. No associations between disease severity and single nucleotide variants of the gene encoding adenosine 2A receptor were detected, implying a dissociation of receptor sensitivity changes and phenotype. The profile of serum caffeine and metabolite levels was identified as a potential diagnostic biomarker by receiver operating characteristic curve analysis.

Conclusion: Absolute lower levels of caffeine and caffeine metabolite profiles are promising diagnostic biomarkers for early PD. This is consistent with the neuroprotective effect of caffeine previously revealed by epidemiologic and experimental studies.

Classification Of Evidence: This study provides Class III evidence that decreased serum levels of caffeine and its metabolites identify patients with PD.

Citing Articles

Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons.

Ngo H, Srivastava A, Le H, Ayer S, Crotty G, Schwarzschild M BMC Neurosci. 2025; 26(1):19.

PMID: 40038582 PMC: 11877714. DOI: 10.1186/s12868-025-00939-7.

Coffee consumption is associated with later age-at-onset of Parkinson's disease.

Kuzovenkova D, Liu L, Gan-Or Z, Ziv G, Senkevich K medRxiv. 2025; .

PMID: 39990543 PMC: 11844581. DOI: 10.1101/2025.02.07.25321819.

Navigating Nutritional Inequality in Schizophrenia: A Comprehensive Exploration of Diet, Genetics, and Holistic Management Across the Life Cycle.

Yan Y, Zhou D, Chen J Nutrients. 2024; 16(21).

PMID: 39519571 PMC: 11547656. DOI: 10.3390/nu16213738.

Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson's disease patients.

Yu Z, Saiki S, Shiina K, Iseki T, Sasazawa Y, Ishikawa K Sci Data. 2024; 11(1):1128.

PMID: 39406833 PMC: 11480472. DOI: 10.1038/s41597-024-03909-6.

Metabolomics Unveils Disrupted Pathways in Parkinson's Disease: Toward Biomarker-Based Diagnosis.

Santos W, Katchborian-Neto A, Viana G, Ferreira M, Martins L, Vale T ACS Chem Neurosci. 2024; 15(17):3168-3180.

PMID: 39177430 PMC: 11378289. DOI: 10.1021/acschemneuro.4c00355.

References

Yamazaki H, Shaw P, Guengerich F, Shimada T . Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol. 1998; 11(6):659-65. DOI: 10.1021/tx970217f. View

Gu L, Gonzalez F, KALOW W, Tang B . Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992; 2(2):73-7. DOI: 10.1097/00008571-199204000-00004. View

Hernan M, Takkouche B, Caamano-Isorna F, Gestal-Otero J . A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002; 52(3):276-84. DOI: 10.1002/ana.10277. View

Ghotbi R, Christensen M, Roh H, Ingelman-Sundberg M, Aklillu E, Bertilsson L . Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol. 2007; 63(6):537-46. DOI: 10.1007/s00228-007-0288-2. View

Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H . (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999; 67(2):189-94. PMC: 1736461. DOI: 10.1136/jnnp.67.2.189. View

Altman R, Lang A, Postuma R . Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord. 2011; 26(13):2427-31. DOI: 10.1002/mds.23873. View

Ascherio A, Chen H, Schwarzschild M, Zhang S, Colditz G, Speizer F . Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology. 2003; 60(5):790-5. DOI: 10.1212/01.wnl.0000046523.05125.87. View

Chen J, Xu K, Petzer J, Staal R, Xu Y, Beilstein M . Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001; 21(10):RC143. PMC: 6762498. View

Tan E, Lu Z, Fook-Chong S, Tan E, Shen H, Chua E . Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(6):634-6. DOI: 10.1002/ajmg.b.30359. View

10.

Fasano A, Bove F, Gabrielli M, Petracca M, Zocco M, Ragazzoni E . The role of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord. 2013; 28(9):1241-9. DOI: 10.1002/mds.25522. View

11.

Hatano T, Saiki S, Okuzumi A, Mohney R, Hattori N . Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry. 2015; 87(3):295-301. DOI: 10.1136/jnnp-2014-309676. View

12.

Rubinsztein D, Codogno P, Levine B . Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012; 11(9):709-30. PMC: 3518431. DOI: 10.1038/nrd3802. View

13.

Che B, Wang L, Zhang Z, Zhang Y, Deng Y . Distribution and accumulation of caffeine in rat tissues and its inhibition on semicarbazide-sensitive amine oxidase. Neurotoxicology. 2012; 33(5):1248-53. DOI: 10.1016/j.neuro.2012.07.004. View

14.

Butler M, Iwasaki M, Guengerich F, Kadlubar F . Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci U S A. 1989; 86(20):7696-700. PMC: 298137. DOI: 10.1073/pnas.86.20.7696. View

15.

Xu K, Xu Y, Chen J, Schwarzschild M . Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 2010; 167(2):475-81. PMC: 2849921. DOI: 10.1016/j.neuroscience.2010.02.020. View

16.

Facheris M, Schneider N, Lesnick T, de Andrade M, Cunningham J, Rocca W . Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord. 2008; 23(14):2033-40. PMC: 4554698. DOI: 10.1002/mds.22247. View

17.

Popat R, Van Den Eeden S, Tanner C, Kamel F, Umbach D, Marder K . Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol. 2011; 18(5):756-65. PMC: 3556904. DOI: 10.1111/j.1468-1331.2011.03353.x. View

18.

Schwarzschild M, Chen J, Ascherio A . Caffeinated clues and the promise of adenosine A(2A) antagonists in PD. Neurology. 2002; 58(8):1154-60. DOI: 10.1212/wnl.58.8.1154. View

19.

Yoritaka A, Shimo Y, Shimo Y, Inoue Y, Yoshino H, Hattori N . Nonmotor Symptoms in Patients with PARK2 Mutations. Parkinsons Dis. 2011; 2011:473640. PMC: 3026966. DOI: 10.4061/2011/473640. View

20.

LeWitt P, Li J, Lu M, Guo L, Auinger P . Metabolomic biomarkers as strong correlates of Parkinson disease progression. Neurology. 2017; 88(9):862-869. PMC: 5331866. DOI: 10.1212/WNL.0000000000003663. View